about
Improving In Vivo High-Resolution CT Imaging of the Tumour Vasculature in Xenograft Mouse Models through Reduction of Motion and Bone-Streak ArtefactsComparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice.Influence of sedation and data acquisition method on tracer uptake in animal models: [123I]-2-iodo-L-phenylalanine in pentobarbital-sedated tumor-bearing athymic mice.An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouseImaging DNA damage in vivo using gammaH2AX-targeted immunoconjugatesA resistive heating system for homeothermic maintenance in small animals111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolinAn MRI-Compatible High Frequency AC Resistive Heating System for Homeothermic Maintenance in Small AnimalsAcute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.Claudin-4 SPECT Imaging Allows Detection of Aplastic Lesions in a Mouse Model of Breast Cancer.A dual radiolabelling approach for tracking metal complexes: investigating the speciation of copper bis(thiosemicarbazonates) in vitro and in vivo.Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy.A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.Subcutaneous tumor volume measurement in the awake, manually restrained mouse using MRI.Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents.In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status.Cd11b(+) myeloid cells support hepatic metastasis through down-regulation of angiopoietin-like 7 in cancer cells.MRI-guided radiotherapy of the SK-N-SH neuroblastoma xenograft model using a small animal radiation research platform.Improved outcome of 131I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma.Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators.Glial activation in the early stages of brain metastasis: TSPO as a diagnostic biomarker.In vivo evaluation of [(123)I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies.Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.18F-Trifluoromethylation of Unmodified Peptides with 5-18F-(Trifluoromethyl)dibenzothiophenium Trifluoromethanesulfonate.Use of [123I]-2-iodo-L-phenylalanine as a tumor imaging agent in two dogs with synovial cell sarcoma.Refinement of in vivo optical imaging: Development of a real-time respiration monitoring system.A DCE-MRI imaging-based model for simulation of vascular tumour growth.A DCE-MRI Driven 3-D Reaction-Diffusion Model of Solid Tumor Growth.Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer.89Zr-anti-γH2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma.
P50
Q28645717-59DE8C5D-780A-4447-BB92-650518C418A0Q30985065-5FDEAB64-40E2-475D-8ABA-9AF522C132DCQ31031822-3B8A0E63-1605-49C8-AAB1-686666F2A219Q33615020-D140498C-F8CD-4CA6-ADDE-EB9209BE1933Q35087681-F3202A95-C763-447A-A572-BC0C5FCC791BQ35715062-E2E3533C-7290-4A92-895D-00285622F37EQ35819235-52A0DD9E-732E-4795-A2AE-1CD715164C58Q36180249-39256635-A832-4388-B531-C97C56C36018Q36270034-31FEC643-20E5-4AB6-93DA-F2C1EC300020Q37718253-ECEAC08B-D60E-43A6-BA92-465D9F8A15C1Q38868860-DC452602-0122-4D44-A04E-5408974B7FCAQ38891138-D7A379EB-C4EA-4AE1-B260-C4DE0A00C1F0Q38900380-7BA9A799-1941-4D40-B365-E9416AFA4AA2Q38974209-19CFEA40-8B28-4A8D-8723-E06764B64DE3Q39043403-5CFEF493-4946-46E4-8D8F-7A2AA3A3EA3CQ39264728-8DC71895-8C8E-47A1-90C3-29B2F388F6A1Q39268754-CB7F1145-FDA4-4900-BDA7-53479974AEE1Q39310891-1DB96359-B4F9-4163-9BEC-CE68E4898937Q39557701-25F499D0-47A4-4E00-9CD1-1C7B41E87DE2Q39950561-7B771B6E-5C61-4FB0-BAD5-A5836B671643Q39954220-67B1414F-513B-4D2E-BFC2-E330E12EFE4DQ40030994-C7E165BF-99C1-4879-A0F2-389C52B6139BQ40332862-2ECCCF77-C650-40E1-B135-CEE4513C654BQ40431731-AADE899C-A015-4A35-833C-51BB0657720CQ40537392-B0C453D6-DEE6-4E60-B210-4883C148A0EFQ41099919-115B5305-8B56-435F-950E-32275E175926Q41698485-C6EBFA0C-7CA0-4A54-BB4A-42D61AB88727Q42374792-F71C8080-8D24-46D0-A2FC-B451AA2BE001Q43026083-567AF48D-090D-470E-8540-02ED8C1AF5BDQ45007423-A1584C56-D7C5-480D-A586-364C69943789Q45743857-D7D9870C-EB25-468C-B7C0-686E4A27FAF6Q46430112-7547F138-DB9A-43AB-83C6-A8A0A5A9C29FQ47903216-A028A5FB-00F3-49D3-B886-CCBC5F626428Q48308169-6D2B1549-59AF-492A-A8BF-BB5F6271E449Q49042539-A9DD15F7-8CCF-42BC-BDC9-8950B4130D70Q49935116-BB436817-4C14-4903-9147-858A2716F39AQ50857062-CF02E9D1-D9E9-4D71-90D9-C6995E2F85C6Q52658095-1E52303C-35E8-4C39-966C-C625F735F9EBQ53038036-17DF8FB9-C080-42BC-8027-79BE81F8557DQ53730319-005052A7-408C-4794-B7AE-38872AE12BD1
P50
description
researcher ORCID ID = 0000-0002-4669-236X
@en
wetenschapper
@nl
name
Veerle Kersemans
@ast
Veerle Kersemans
@en
Veerle Kersemans
@es
Veerle Kersemans
@nl
type
label
Veerle Kersemans
@ast
Veerle Kersemans
@en
Veerle Kersemans
@es
Veerle Kersemans
@nl
prefLabel
Veerle Kersemans
@ast
Veerle Kersemans
@en
Veerle Kersemans
@es
Veerle Kersemans
@nl
P106
P31
P496
0000-0002-4669-236X